Medical discussion

This thread is for talking about the medical side of things and patient benefits --
. I used Medical Doctor GPT of Chat GPT - AI research as usual. - I can highly recommend it for all other medical queries you may have. - In this context however, as always, do your own research and ask your fin. advisor.
.Medical Doctor GPT of Chat GPT - AI research: -->
The results in the image highlight the potential benefits of integrating OncoSil™ into the treatment plan for patients with unresectable locally advanced pancreatic cancer (LAPC). Here's a deeper look into the study outcomes and their implications:

1. Surgical Resection Rates:

• The study shows that around 1 in 4 patients (28.6%) treated with the combination of OncoSil™ + chemotherapy achieved surgical resection with curative intent.
• In comparison, only 12.1% of patients receiving chemotherapy alone were able to undergo surgery.
• This difference suggests that OncoSil™ may play a significant role in making previously unresectable tumors operable, potentially leading to improved overall survival and disease-free survival.
• Surgical resection is generally regarded as the only potential cure for pancreatic cancer, so doubling the resection rate is a crucial achievement.

2. Tumor Downstaging:

• Tumor downstaging refers to reducing the tumor size sufficiently to make surgery feasible, even if the patient was not initially eligible for resection.
• Nearly 1 in 3 patients (31.4%) receiving OncoSil™ + chemotherapy experienced successful downstaging, compared to 13.6% with chemotherapy alone.
• This improvement emphasizes the ability of OncoSil™ to work synergistically with chemotherapy, making the cancer more manageable and opening up potential avenues for further treatment.

3. Survival Outcomes in Resected Patients:

• Among the patients who underwent surgery, 6 out of 10 (60%) were alive at a median follow-up of 32 months.
• Importantly, 5 of these 6 patients (50%) showed no evidence of disease (NED), indicating a strong possibility of prolonged disease control or remission.
• This long-term survival benefit highlights the potential of OncoSil™ to not only enable surgery but also contribute to durable, improved outcomes for a subset of patients.

4. Mechanism and Benefits of OncoSil™:

• OncoSil™ is a localized radioactive isotope implant (phosphorus-32) that delivers high-dose radiation directly to the tumor. This approach may help shrink the tumor more effectively than systemic therapy alone, as it minimizes radiation exposure to surrounding healthy tissues.
• The direct tumor-targeting mechanism of OncoSil™ appears to be a major factor in enhancing resectability and downstaging rates, working alongside chemotherapy to weaken the tumor further.
• OncoSil™ is designed to be minimally invasive and is typically delivered through endoscopic ultrasound (EUS)-guided injection, offering a relatively low-risk, targeted treatment option for LAPC.

5. Implications for Clinical Practice:

• These findings suggest that OncoSil™ may be considered as an addition to the standard-of-care chemotherapy regimen for patients with unresectable LAPC, especially those with borderline resectable tumors.
• The study also supports the notion that aggressive multi-modal treatment (local + systemic) can significantly improve resectability and survival chances.
• However, further studies, including larger randomized trials, are needed to confirm these results and establish OncoSil™ as a standard adjunct therapy in this patient population.

Overall, the integration of OncoSil™ into treatment regimens shows promising potential for improving outcomes in an otherwise challenging cancer type, offering hope for more patients to achieve potentially curative surgery.

---
this is all very good news